Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospital, Basel, Switzerland | OTHER |
The main objective of this observational study is to characterize new users of quetiapine XR as well as new users of other study drugs (i.e. the comparison group) and to quantify the risk of developing newly diagnosed outcomes of interest in new users of quetiapine XR as well as in other study drugs.
Epidemiology study to assess the safety of a new slow-release form of Seroquel (quetiapine) in the post-marketing phase in the UK.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Quetiapine XR group | |||
| Non-quetiapine comparison group |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The outcome of interest will be evaluated by means of relative risk based on incidence rates estimates in users of quetiapine XR vs corresponding incidence rates in users of comparison drugs | During follow-up of a treatment episode estimated to be on average of 1.5 years | |
| Duration of treatment | During follow-up estimated to be on average of 1.5 years. | |
| Duration of treatment episode | Episode, defined as the treatment time from first to last prescription of quetiapine XR or other study drugs. | During follow-up estimated to be on average of 1.5 years |
| Comorbidities defined by clinical diagnosis or prescription | Baseline and during follow up of treatment estimated to be on average 1.5 years | |
| Age | Baseline | |
| Gender | Baseline | |
| Dose | During follow-up of treatment estimated to be on average 1.5 years | |
| Adherence | During follow-up of treatment estimated to be on average 1.5 years | |
| The number of subjects to whom the drug was prescribed by the general practitioners. | The number of patients, whom the drug was prescribed by the specified type of prescriber (specialist, general practitioner or another type of physician). |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
A sample of the general population in the UK consisting of 3 millions inhabitants.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Christoph R Meier, PROF DR PHIL | University hospital of Basel, Switzerland | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Basel | Basel | Switzerland |
Not provided
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| D003865 | Depressive Disorder, Major |
| D001714 | Bipolar Disorder |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| During follow-up of treatment estimated to be on average 1.5 years |
| Indication for treatment | During follow-up of treatment estimated to be on averaged 1.5 years |
| D000068105 | Bipolar and Related Disorders |